Case - Papulopustular Drug Eruption Due to an Epidermal Growth Factor Receptor Inhibitors, Erlotinib and Cetuximab

	Unregistered User Click here if this is not your Personal Edition
		Contact Us \| Free E-Mail Updates \| Journals \| Register a colleague

Dermatology Other

EXPLORE :

Most Read News

All Webcasts / CME

Warning | Privacy

Recent cases - Dermatology Other

	Esophageal Squamous Cell Carcinoma Presenting with Extensive Skin Lesions: A Case Report
	Selective IgM Deficiency Accompanied with IgG4 Deficiency, Dermal Complications and a Bronchial Polyp
	Giant Pyogenic Granuloma of the Thigh: A Case Report
	Atypically Distributed Cutaneous Lesions of Norwegian Scabies in an HIV-Positive Man in South India: A Case Report
	Merkel Cell Carcinoma of the Upper Extremity: Case Report and Update

Recent news - Dermatology Other

	Linezolid Shows Efficacy for Complicated Skin and Soft-Tissue Infections: Presented at ECCMID - (DGDispatch)
	Iclaprim Eradicates Complicated Skin and Skin Structure Infections: Presented at ECCMID - (DGDispatch)
	Becaplermin May Increase Risk of Death From Cancer in Patients With Diabetes - (DGNews)
	As Use of Biologicals Rises, So Too Will Cutaneous Reactions to Them: Presented at AAAAI - (DGDispatch)
	FDA Approves Rilonacept for the Treatment of Rare Inflammatory Syndromes - (DGNews)

Recent webcasts/CME - Dermatology Other

	Advances in Dermatological Care: What the Family Physician Needs to Know
	Distinguishing Pemphigus and Pemphigoid for the Non-Dermatologist
	Actinic Keratoses: What You Must Know About Prevention, Diagnosis, and Treatment
	Don't Sweat it: Epidemiology, Pathophysiology, and Treatment of Hyperhidrosis

personal edition > dermatology other > cases

Cases

E-Mail this case to a colleague

Papulopustular Drug Eruption Due to an Epidermal Growth Factor Receptor Inhibitors, Erlotinib and Cetuximab

Presented by:	Dermatology Online Journal / Jennifer Bragg MD and Miriam Keltz Pomeranz MD
Summary points:	This case report describes two patients who present with papulopustular eruptions -- a 56-year-old receiving cetuximab for metastatic lung cancer and a 53-year-old receiving erlotinib for metastatic rectal cancer. The case describes the findings from bacterial cultures, treatment, and outcomes. The authors discuss the common side effects of epidermal growth factor receptor and the correlation between the presence and severity of eruption and response to treatment.
Accreditation:	Not available
Other:

Additional Information